Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Summary

Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16 weeks, safety/tolerability of secukinumab and evaluate the impact of the treatment on quality of life and work productivity in subjects with moderate to severe plaque psoriasis in the Turkish population.

Timeline

Start

2016-06

Primary completion

2017-03

Completion

2017-03

Drugs

Indications